At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Closed 09-23 16:00:00 EDT
1.32
-0.05
-3.65%
盘后1.32
+0.00-0.08%
19:45 EDT
High1.36Low1.30Vol627.03K
Open1.35D1 Closing1.37Amplitude4.38%
Mkt Cap80.09MTradable Cap73.40MTotal Shares60.67M
T/O831.14KT/O Rate1.13%Tradable Shares55.61M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Maia Biotech Wins Spanish, Portuguese Regulatory Clearance to Screen Patients in THIO-104 Lung Cancer Trial
Reuters  ·  09-23 21:17
Maia Biotech Wins Spanish, Portuguese Regulatory Clearance to Screen Patients in THIO-104 Lung Cancer Trial
Maia Biotechnology Expands Pivotal Phase 3 Thio-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
THOMSON REUTERS  ·  09-23 21:17
Maia Biotechnology Expands Pivotal Phase 3 Thio-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
Maia Biotechnology - Targets 100 Patients Dosed in Thio-104 by Year-End 2026; Interim Analysis in 2027
THOMSON REUTERS  ·  09-23 21:17
Maia Biotechnology - Targets 100 Patients Dosed in Thio-104 by Year-End 2026; Interim Analysis in 2027
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
GlobeNewswire  ·  09-23 21:17
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
Maia Biotech Says Phase 3 THIO-104 Trial in Third-Line NSCLC Enrolls 65 Patients
Reuters  ·  09-22 20:47
Maia Biotech Says Phase 3 THIO-104 Trial in Third-Line NSCLC Enrolls 65 Patients
Maia Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  09-22 20:47
Maia Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
GlobeNewswire  ·  09-22 20:47
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Maia Biotechnology Wins $2.3 Million NIH Grant for Phase 2 NSCLC Trial Expansion
Reuters  ·  09-16
Maia Biotechnology Wins $2.3 Million NIH Grant for Phase 2 NSCLC Trial Expansion
Maia Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
THOMSON REUTERS  ·  09-16
Maia Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
GlobeNewswire  ·  09-16
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Maia Biotechnology Board Member Ramiro Guerrero Boosts Stake with USD 252,284 Share Buy
Reuters  ·  09-15
Maia Biotechnology Board Member Ramiro Guerrero Boosts Stake with USD 252,284 Share Buy
Maia Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
THOMSON REUTERS  ·  09-15
Maia Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
Maia Biotechnology - Directors and Officers Hold 21.34% Stake as of Sept 14, 2026
THOMSON REUTERS  ·  09-15
Maia Biotechnology - Directors and Officers Hold 21.34% Stake as of Sept 14, 2026
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
GlobeNewswire  ·  09-15
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
MAIA Biotechnology Director Makes Bold Insider Move With Fresh Stock Purchase
TIPRANKS  ·  09-15
MAIA Biotechnology Director Makes Bold Insider Move With Fresh Stock Purchase
Maia Biotechnology Director Ramiro Guerrero Acquires 37,595 Common Shares Worth $49,511.38
Reuters  ·  09-14
Maia Biotechnology Director Ramiro Guerrero Acquires 37,595 Common Shares Worth $49,511.38
MAIA Biotechnology Presents Next-Generation Telomere-Targeting Cancer Drug Candidates at IRT 2026
Reuters  ·  09-10
MAIA Biotechnology Presents Next-Generation Telomere-Targeting Cancer Drug Candidates at IRT 2026
Maia Bio Director Ramiro Guerrero Buys 133,790 Shares Worth $185,114.90
Reuters  ·  09-02
Maia Bio Director Ramiro Guerrero Buys 133,790 Shares Worth $185,114.90
Maia Bio Director Ramiro Guerrero Acquires 1,794 Common Shares Worth $2,386.02
Reuters  ·  08-26
Maia Bio Director Ramiro Guerrero Acquires 1,794 Common Shares Worth $2,386.02
Maia Biotechnology Director Ramiro Guerrero Reports Purchase of 11,899 Common Shares for $16,301.63
Reuters  ·  08-25
Maia Biotechnology Director Ramiro Guerrero Reports Purchase of 11,899 Common Shares for $16,301.63

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--